ACP
DMRA

Arcus Capital Partners’s Damora Therapeutics DMRA Stock Holding History

Arcus Capital Partners’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19
Closed -$557 – 204
2022
Q4 		$557 Buy
+19
New +$788 ﹤0.01% 345

Other funds holding DMRA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Arcus Capital Partners's DMRA Position: Q1 2023 in Review

Arcus Capital Partners sold out of Damora Therapeutics (DMRA) in Q1 2023, closing a stake of 19 shares — an estimated $557 sold.

Arcus Capital Partners first reported a position in DMRA in Q4 2022 and held it in 1 quarter. The position peaked at $557 in Q4 2022. 26 funds tracked by Wall St. Rank hold DMRA as of Q1 2023.

  • Arcus Capital Partners reported no remaining Damora Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Arcus Capital Partners sold 19 Damora Therapeutics shares in Q1 2023, an estimated $557.
  • Arcus Capital Partners first reported a position in Damora Therapeutics in Q4 2022 and held it in 1 quarter.
  • Arcus Capital Partners's Damora Therapeutics position peaked at $557 in Q4 2022.
  • 26 funds tracked by Wall St. Rank held Damora Therapeutics as of Q1 2023.

Based on Arcus Capital Partners's 13F filing for Q1 2023, filed 9 May 2023.